9 Things to Know About Fezolinetant — the First Neurokinin Receptor Drug for Hot Flashes
When fezolinetant hit the news, the headlines ranged from 'menopause cure' to 'barely works' — neither of which is honest. What's actually true is more interesting: this is the first drug ever designed specifically around the brain chemistry of hot flashes, not repurposed from something else. That alone feels like the medical world finally paying attention to something women have been living with for a very long time.
Learn more about Rose →It targets the KNDy neuron pathway — the actual thermostat gone wrong
Hot flashes happen because estrogen withdrawal disrupts neurons in the hypothalamus called KNDy neurons, which regulate core body temperature. When estrogen drops, these neurons become overactive and release a signalling peptide called neurokinin B (NKB), which binds to NK3 receptors and triggers the sudden heat-dissipation cascade experienced as a hot flash. Fezolinetant blocks the NK3 receptor specifically, interrupting that signal at its source rather than replacing estrogen or sedating the nervous system broadly.
It is genuinely non-hormonal — not just 'hormone-free' in a marketing sense
Unlike some treatments labeled non-hormonal that still influence estrogen metabolism or receptor activity indirectly, fezolinetant has no hormonal mechanism whatsoever. It does not raise or lower estrogen, progesterone, or testosterone levels, and it does not act on estrogen receptors anywhere in the body. This distinction matters for women who avoid hormones due to hormone-sensitive cancers, blood clot history, or personal preference, because the drug operates on an entirely separate biological system.
The SKYLIGHT trials showed meaningful reductions in hot flash frequency and severity
The pivotal Phase 3 trials — SKYLIGHT 1 and SKYLIGHT 2 — enrolled over 1,000 women with moderate-to-severe vasomotor symptoms and tested fezolinetant 30 mg and 45 mg daily against placebo over 12 weeks. Both doses significantly reduced the frequency and severity of hot flashes compared to placebo, with the 45 mg dose showing the strongest effect; at week 12, women on 45 mg were having roughly 60% fewer hot flashes than at baseline. A long-term safety extension (SKYLIGHT 4) followed participants for 52 weeks without new safety signals emerging.
It works faster than many non-hormonal alternatives
Women in the SKYLIGHT trials began seeing statistically significant reductions in hot flash frequency as early as week 1, which is notably quicker than antidepressants like venlafaxine or SSRIs that typically take 2–4 weeks to show vasomotor benefit. By week 4, a substantial proportion of participants had reached their maximum reduction in symptoms. This speed of onset is clinically relevant for women who are severely sleep-deprived or functionally impaired by their symptoms.
The ideal candidate is someone who needs effective relief but has a reason to avoid hormones
Fezolinetant was developed precisely for the gap between 'HRT works well but I can't take it' and 'nothing else works well enough.' Women with a history of hormone-sensitive breast cancer, deep vein thrombosis, or unexplained vaginal bleeding — groups for whom estrogen-based HRT carries real risk — are the population most likely to benefit meaningfully from having this option. It is also relevant for women who have made an informed choice to avoid hormones but find that lifestyle adjustments and existing non-hormonal drugs aren't providing adequate relief.
Liver enzyme elevations were seen in a small number of trial participants — this is the main safety watch point
In the SKYLIGHT 4 long-term trial, a small percentage of women on fezolinetant experienced elevated liver enzymes (transaminases), which led the FDA to require liver function monitoring at baseline, 3 months, and 6 months of treatment. The elevations were generally asymptomatic and resolved on discontinuation, but the drug is contraindicated in women with cirrhosis or severe hepatic impairment. Anyone prescribed fezolinetant should ensure their prescriber knows about any existing liver conditions or regular alcohol use.
It does not treat genitourinary symptoms, bone loss, or mood — only vasomotor symptoms
Because fezolinetant has no hormonal activity, it offers none of the broader systemic benefits that estrogen-based HRT provides, including protection against bone density loss, relief from vaginal dryness or painful sex, or stabilisation of mood fluctuations linked to estrogen variability. Women choosing fezolinetant for hot flashes who also have significant genitourinary syndrome of menopause or are concerned about osteoporosis will need separate strategies for those issues. This is not a criticism of the drug — it simply does what it was designed to do, and nothing more.
Compared to HRT, it is effective but less comprehensive — context determines which makes more sense
Head-to-head trials comparing fezolinetant directly to estrogen-based HRT do not yet exist, so direct efficacy comparisons rely on cross-trial inference rather than controlled data. What the available evidence suggests is that HRT remains the most effective intervention for vasomotor symptoms overall, while fezolinetant offers a genuinely effective alternative for women in whom HRT is contraindicated or declined. For women without contraindications who are undecided, this is a conversation worth having with a menopause-informed clinician rather than a decision made on access alone.
Access and cost remain significant barriers in many countries
As of 2024, fezolinetant is approved in the United States and the European Union, but reimbursement and formulary coverage vary widely, and out-of-pocket costs in the US can be substantial without insurance coverage. In the UK, the MHRA approved it in 2023 under the name Veoza, but NHS prescribing pathways were still being established. Women interested in fezolinetant who are being told it's unavailable or unaffordable are encouraged to ask specifically about patient assistance programs and to revisit the question as coverage evolves, since access landscapes for newly approved drugs typically shift significantly in the first two to three years post-approval.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.